Should topiramate be initial therapy in the management of idiopathic intracranial hypertension?: A literature review

Author:

Goyal Abhishek1,Zarroli Katherine2ORCID

Affiliation:

1. Kasturba Medical College, MAHE, Manipal, India

2. Department of Neurology, University of Florida College of Medicine - Jacksonville, Jacksonville, FL, USA.

Abstract

Idiopathic intracranial hypertension (IIH) is a condition of unknown etiology that primarily affects obese women of childbearing age. Symptoms include disabling headaches, visual disturbances, and intracranial noises (pulsatile tinnitus). Currently, no standardized treatment guidelines are available and the current management focuses on weight loss and acetazolamide use. There is an increasing body of evidence suggesting that the initial use of topiramate may be considered in IIH treatment. Acetazolamide is the recommended initial treatment for IIH, with topiramate often used as a second-line agent. Topiramate has multiple benefits to indicate it would pose effective in IIH management. Through varying mechanisms, it leads to weight loss and improves migraine headache control, the most common headache phenotype in IIH. Topiramate also inhibits the carbonic anhydrase enzyme like acetazolamide to reduce intracranial pressure and treat papilledema. The safety profile of topiramate is comparable or superior to acetazolamide. To date, there are limited studies comparing topiramate to acetazolamide or other treatment modalities in IIH. Based on its varying mechanisms of action, topiramate is a strong potential treatment agent for IIH, yet acetazolamide is often chosen first-line. However, the data supporting use of acetazolamide or topiramate is inefficient to designate one agent preferred over the other. There is a need for further studies assessing topiramate use in the treatment of IIH, and comparing topiramate use to other treatment modalities.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference29 articles.

1. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions.;Markey;Lancet Neurol,2016

2. The expanding burden of idiopathic intracranial hypertension.;Mollan;Eye (Lond),2019

3. Incidence, prevalence and healthcare outcomes in idiopathic intracranial hypertension: a population study.;Miah;Neurology,2021

4. Interventions for idiopathic intracranial hypertension.;Piper;Cochrane Database Syst Rev,2015

5. Ueber meningitis serosa und verwandte zustände.;Quincke;Dtsch Z Nervenheilkd,1897

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3